AN2 Therapeutics, Inc. (ANTX)
NASDAQ
5.05
+0.15 (+3.06%)
Closed
Sep 18, 2026
Day's Range
4.805.15
52 wk Range
1.007.19
Financial Statements - ANTX - AN2 Therapeutics, Inc.
Revenue
0
Net Income
-35.17M▲ 31.5%
EBITDA
-38.10M▲ 27.2%
Free Cash Flow
-29.83M▲ 39.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -38.10M | -54.55M | -69.63M | -42.26M | -21.57M | -7.28M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 1K | -2.23M | 4.90M | 1.30M | -38K | -6.32M |
| Pre Tax Income | -35.17M | -51.32M | -64.73M | -40.95M | -21.54M | -13.60M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -35.17M | -51.32M | -64.73M | -40.95M | -21.54M | -13.60M |
| EPS Basic | -1.16 | -1.72 | -2.74 | -2.79 | -1.546766 | -0.968345 |
| EPS Diluted | -1.16 | -1.72 | -2.74 | -2.79 | -1.546766 | -0.968345 |
| Basic Shares Outstanding | 30.21M | 29.82M | 23.60M | 15.34M | 18.13M | 14.04M |
| Diluted Shares Outstanding | 30.21M | 29.82M | 23.60M | 15.34M | 18.13M | 14.04M |
| Ebit | -38.10M | -54.55M | -69.63M | -42.26M | -21.57M | -7.28M |
| Ebitda | -38.10M | -52.32M | -69.63M | -42.26M | -21.57M | -7.28M |
| Net Income Continuous Operations | -35.17M | -51.32M | -64.73M | -40.95M | -21.54M | -13.60M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | 6.51M | 981K |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
